Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439393 | 0.85 | RXFP1 (0.74) | RXFP1L3MBTL1KDM4ETDP1TAAR1 | |
| SCHEMBL13589544 | 0.83 | MDM2 (0.61) | MDM2EPHX1L3MBTL1KDM4ETYK2 | |
| SCHEMBL18920315 | 0.82 | MDM2 (0.59) | MDM2EPHX1L3MBTL1KDM4ETYK2 | |
| SCHEMBL13134219 | 0.79 | RXFP1 (0.49) | RXFP1L3MBTL1KDM4ETDP1RAB9A | |
| SCHEMBL25433129 | 0.79 | MDM2 (0.52) | MDM2EPHX1L3MBTL1KDM4ETYK2 | |
| SCHEMBL219147 | 0.79 | KDM4E (0.66) | RXFP1EPHX1L3MBTL1KDM4ETDP1 | |
| SCHEMBL17084525 | 0.79 | RXFP1 (0.67) | RXFP1L3MBTL1KDM4ETDP1TSHR | |
| SCHEMBL48610 | 0.79 | TSHR (0.69) | MDM2EPHX1L3MBTL1KDM4ETDP1 | |
| SCHEMBL12181323 | 0.79 | MDM2 (0.54) | MDM2EPHX1L3MBTL1KDM4ETYK2 | |
| SCHEMBL12828408 | 0.78 | RAB9A (0.67) | KDM4ETDP1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4065616-B1 | POLYMER CONETWORKS OF POLY(PYRIDINE-(METH)-ACRYLAMIDE) DERIVATIVES-CROSSLINKED BY TRANSITION METAL IONS- AND LINKED BY POLYDIMETHYLSILOXANE DERIVATIVES | LUXEMBOURG INST SCIENCE & TECH LIST (LU) | 2023-08-23 | — | — | EP | disclosed |
| US-20230008301-A1 | POLYMER CONETWORKS OF POLY(PYRIDINE-(METH)-ACRYLAMIDE) DERIVATIVES- CROSSLINKED BY TRANSITION METAL IONS-AND LINKED BY POLYDIMETHYLSILOXANE DERIVATIVES | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LIST) (LU) | 2023-01-12 | — | — | US | disclosed |
| WO-2021105349-A1 | POLYMER CONETWORKS OF POLY(PYRIDINE-(METH)-ACRYLAMIDE) DERIVATIVES-CROSSLINKED BY TRANSITION METAL IONS- AND LINKED BY POLYDIMETHYLSILOXANE DERIVATIVES | LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LIST) (LU) | 2021-06-03 | — | — | WO | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| EP-0134535-B1 | 1,6-NAPHTHYRIDIN DERIVATIVES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0101952-B1 | 5-ALKYL-1,6-NAPHTHYRIDIN-2(1H)-ONES, INTERMEDIATES, THEIR PREPARATION AND THEIR CARDIOTONIC USE | STERLING DRUG INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0204335-A2 | 2(1H)-Pyridin-ones useful as intermediates | STERLING DRUG INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4604399-A | 5-methyl(or ethyl)-1,6-naphthyridin-2(1H)-one 6-oxides, their preparation and the cardiotonic use thereof | STERLING DRUG INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4532247-A | Increases cardiac contractility | STERLING DRUG INC. (US) | 1985-07-30 | — | — | US | disclosed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0134535-A1 | 1,6-Naphthyridin derivatives useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | RXFP1 812/4885MDM2 1048/4885EPHX1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.